Jim Simons Solid Biosciences Inc. Transaction History

Renaissance Technologies LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.51 - $7.56 $207,397 - $3.07 Million	-406,661 Reduced 28.66%	1,012,270 $472,000
Q2 2022 Aug 12, 2022	BUY	$0.43 - $1.24 $64,653 - $186,441	150,356 Added 11.85%	1,418,931 $873,000
Q1 2022 May 13, 2022	BUY	$0.74 - $1.79 $488,952 - $1.18 Million	660,747 Added 108.71%	1,268,575 $1.52 Million
Q4 2021 Feb 11, 2022	BUY	$1.69 - $2.46 $348,111 - $506,718	205,983 Added 51.26%	607,828 $1.06 Million
Q3 2021 Nov 12, 2021	BUY	$2.38 - $3.77 $40,602 - $64,316	17,060 Added 4.43%	401,845 $960,000
Q2 2021 Aug 13, 2021	BUY	$3.49 - $5.51 $1.34 Million - $2.12 Million	384,785 New	384,785 $1.41 Million
Q1 2021 May 13, 2021	SELL	$5.37 - $10.72 $398,722 - $795,960	-74,250 Closed	0 $0
Q4 2020 Feb 10, 2021	SELL	$3.08 - $7.79 $72,078 - $182,301	-23,402 Reduced 23.96%	74,250 $563,000
Q3 2020 Nov 13, 2020	SELL	$2.02 - $3.08 $66,352 - $101,171	-32,848 Reduced 25.17%	97,652 $198,000
Q2 2020 Aug 13, 2020	BUY	$2.1 - $3.42 $92,292 - $150,305	43,949 Added 50.78%	130,500 $382,000
Q1 2020 May 14, 2020	BUY	$2.31 - $4.43 $65,860 - $126,303	28,511 Added 49.12%	86,551 $207,000
Q4 2019 Feb 13, 2020	BUY	$2.82 - $12.9 $72,586 - $332,046	25,740 Added 79.69%	58,040 $258,000
Q3 2019 Nov 13, 2019	SELL	$4.33 - $11.64 $510,940 - $1.37 Million	-118,000 Reduced 78.51%	32,300 $334,000
Q2 2019 Aug 12, 2019	BUY	$4.6 - $10.13 $247,939 - $546,007	53,900 Added 55.91%	150,300 $864,000
Q1 2019 May 14, 2019	BUY	$7.19 - $32.37 $693,116 - $3.12 Million	96,400 New	96,400 $887,000

Ticker SLDB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 7,533,080
Market Cap $22.7M
Description
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candid...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.